Preventing early cardiovascular death in patients with familial hypercholesterolemia

Journal of the American Osteopathic Association

Volumn 114, Issue 2, 2014, Pages 99-108

  Repas, Thomas B ^a,b,c,d   Ross Tanner, J ^a,b,c,d  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Department at the Regional Medical Clinic ^*  (United States)

^c Diabetes and Lipid Clinic of Alaska   (United States)

^d Pacific Northwest University of Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASES; COMPLICATION; EPIDEMIOLOGY; HUMAN; HYPERLIPOPROTEINEMIA TYPE II; MORTALITY; SURVIVAL RATE; TRENDS; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; SURVIVAL RATE; UNITED STATES;

EID: 84893354858     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: 10.7556/jaoa.2014.023     Document Type: Article

References (50)

1. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung H; Division of Vital Statistics. Deaths: final data for 2009. Natl Vital Stat Rep. 2011;60(3):1-117. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_03.pdf. Accessed January 8, 2014.
2. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-2398. http://www.nejm.org/doi/full/10.1056/NEJMsa053935. Accessed November 25, 2012.
3. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000 [published online March 1, 2004]. Circulation. 2004;109(9):1101-1107. http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=14993137. Accessed November 25, 2012.
4. Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation. 2000;102(13):1511-1516. http://circ.ahajournals.org/content/102/13/1511.long. Accessed November 25, 2012.
5. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol. 2005;162(8):764-773. http://aje.oxfordjournals.org/content/162/8/764.long. Accessed November 25, 2012.
6. World Health Organization. Familial Hypercholesterolaemia (FH): Report of a Second WHO Consultation. Geneva, Switzerland: World Health Organization Human Genetics Programme; 1999. http://whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS _99.2.pdf. Accessed August 3, 2012.
7. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3):133-140.
8. Defesche JC. Defining the challenges of FH screening for familial hypercholesterolemia. J Clin Lipidol. 2010;4(5):338-341. doi:10.1016/j.jacl.2010.08.022.
9. Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173(1):55-68.
10. Qureshi N, Humphries SE, Seed M, et al. Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract. 2009;59(567):773-776. doi:10.3399/bjgp09X472674.
11. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006;174(8):1124-1129. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1421462/pdf/20060411s00026p1124.pdf. Accessed August 3, 2012.
12. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133-170. doi:10.1146/annurev.ge.24.120190.001025.
13. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol. 2008;19(4):362-368. doi:10.1097/MOL.0b013e32830636e5.
14. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303(6807):893-896. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1671226/pdf/bmj00148-0031.pdf. Accessed August 3, 2012.
15. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;2(21):2625-2633 [published online October 7, 2008]. doi:10.1093/eurheartj/ehn422.
16. Schuster H. High risk/high priority: familial hypercholesterolemia-a paradigm for molecular medicine. Atheroscler Suppl. 2002;2(4):27-30.
17. Foody JM. Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice [published online November 5, 2013]. Clin Cardiol. doi:10.1002/clc.22223.
18. Grosse SD, Boyle CA, Botkin JR; Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis. MMWR Recomm Report. 2004;53(RR-13):1-36. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5313a1.htm. Accessed January 8, 2014.
19. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287-1301.
20. Shin M, Besser LM, Kucik JE, et al; Congenital Anomaly Multistate Prevalence and Survival Collaborative. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics. 2009;124(6):1565-1571. doi:10.1542/peds.2009-0745.
21. Diabetes Public Health Resource. Children and diabetes-more information. Centers for Disease Control and Prevention website. http://www.cdc.gov/diabetes/projects/cda2.htm. Accessed August 3, 2012.
22. Civeira F, Castillo S, Alonso R, et al. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation [published online July 14, 2005]. Arterioscler Thromb Vasc Biol. 2005;25(9):1960-1965. http://atvb.ahajournals.org/content /25/9/1960.full. Accessed November 25, 2012.
23. Descamps OS, Leysen X, Van Leuven F, Heller FR. The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. Atherosclerosis. 2001;157(2):514-518.
24. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357(9251):165-168.
25. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171-176.
26. Wiegman A, Rodenburg J, de Jongh S, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation. 2003;107(11):1473-1478. http://circ.ahajournals.org/content/107/11/1473.full.pdf+html. Accessed August 3, 2012.
27. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. doi:10.1136/bmj.a2423.
28. Hemphill LC. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis [published online August 20, 2010]. J Clin Lipidol. 2010;4(5):346-349. doi:10.1016/j.jacl.2010.08.013.
29. Ballantyne CM, Houri J, Notarbartolo A, et al; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial [published online April 28, 2003]. Circulation. 2003;107(19):2409-2415. doi:10.1161/01.CIR.0000068312.21969.C8.
30. Kuo PT, Kostis JB, Moreyra AE, Hayes JA. Familial type II hyperlipoproteinemia with coronary heart disease: effect of diet-colestipol-nicotinic acid treatment. Chest. 1981;79(3): 286-291.
31. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115(14):1948-1967. http://circ.ahajournals.org/content/115/14/1948.full.pdf. Accessed August 3, 2012.
32. Zappalla FR, Gidding SS. Lipid management in children. Endocrinol Metab Clin North Am. 2009;38(1):171-183. doi:10.1016/j.ecl.2008.11.006.
33. Daniels SR, Greer FR; Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198-208. doi:10.1542/peds.2008-1349.
34. de Ferranti S, Ludwig DS. Storm over statins-the controversy surrounding pharmacologic treatment of children. N Engl J Med. 2008;359(13):1309-1312. doi:10.1056/NEJMp0805953. http://www.nejm.org/doi/full/10.1056/NEJMp0805953. Accessed January 8, 2014.
35. Browne B, Vasquez S. Pediatric dyslipidemias: prescription medication efficacy and safety [published online April 12, 2008]. J Clin Lipidol. 2008;2(3):189-201. doi:10.1016/j.jacl.2008.04.008.
36. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74-80.
37. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106(17):2231-2237. http://circ.ahajournals.org/content/106/17/2231.full.pdf. Accessed January 8, 2014.
38. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331-337.
39. Kermani T, Frishman WH. Nonpharmacologic approaches for the treatment of hyperlipidemia. Cardiol Rev. 2005;13(5):247-255.
40. Mehta PK, Baer J, Nell C, Sperling LS. Low density lipoprotein apheresis as a treatment option for hyperlipidemia. Curr Treat Options Cardiovasc Med. 2009;11(4):279-288.
41. Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Ther Apher Dial. 2003;7(4):382-390.
42. American Society for Apheresis. Therapeutic Apheresis: A Guide to Billing and Securing Appropriate Reimbursement. Vancouver, British Columbia, Canada: American Society for Apheresis; 2013. http://www.apheresis.org/resource/resmgr/files/asfa_therapeutic_apheresis_r.pdf. Accessed January 8, 2014.
43. LIPOSORBER [package insert]. New York, NY: Kaneka Pharma America; 2010. http://www.liposorber.com/physician/prescribe/prescribe.htm. Accessed March 12, 2011.
44. Moriarty PM, Gibson CA, Kensey KR, Hogenauer W. Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. Am J Cardiol. 2004;93(8):1044-1046.
45. Moriarty PM, Gibson CA. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am J Cardiol. 2005;95(10):1246-1247.
46. Bosch T, Wendler T. State of the art of low-density lipoprotein apheresis in the year 2003. Ther Apher Dial. 2004;8(2):76-79.
47. Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. J Am Coll Cardiol. 2002;40(2):220-227. http://content.onlinejacc.org/article.aspx?articleid=1130199. Accessed August 3, 2012.
48. Mabuchi H, Koizumi J, Shimizu M, et al; for the Hokuriku-FH-LDL-Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol. 1998;82(12):1489-1495.
49. Sibley C, McGann S, Stone NJ. Long-term survival of childhood coronary artery disease in a patient severely affected with familial hypercholesterolemia. Am J Cardiol. 2004;94(5):699-700.
50. Patient information from the Foundation of the National Lipid Association. Learn Your Lipids website. http://www.learnyourlipids.com. Accessed August 3, 2012.